Role of PPAR-γ ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 7, 2003, Pages 2999-3004

  Aoun, Paul ^a   Simpkins, James W ^a   Agarwal, Neeraj ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ANTIOXIDANT; ASPARTIC ACID DERIVATIVE; BUTHIONINE SULFOXIMINE; DIZOCILPINE; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; LIGAND; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUTRAL RED; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THIOUREA; THREO BETA BENZYLOXYASPARTATE; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG INDICATION; GLAUCOMA; IMMUNOBLOTTING; INSULIN SENSITIVITY; NEUROPROTECTION; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RETINA DISEASE; RETINA GANGLION CELL;

ANIMALS; ANTIOXIDANTS; BUTHIONINE SULFOXIMINE; CELL LINE, TRANSFORMED; CELL SURVIVAL; CHROMANS; CYTOPROTECTION; GLUTAMIC ACID; LIGANDS; NEUROPROTECTIVE AGENTS; PROSTAGLANDIN D2; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RETINAL GANGLION CELLS; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0037562669     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-1060     Document Type: Article

References (47)

1. Lemberger T, Braissant O, Juge-Aubry C, et al. PPAR tissue distribution and interactions with other hormone-signaling pathways. Ann NY Acad Sci. 1996;804:231-251.
2. Dreyer C, Krey G, Keller H, Givel F, Helfetbein G, Wahli W. Control of the peroxisomal b-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992;68:879-887.
3. Krey G, Braissant O, L'Horest F, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator dependent receptor ligand assay. Mol Endocrinol. 1997;11:779-791.
4. Elangbam CS, Tyler RD, Lightfoot RM. Peroxisome proliferator activated receptors in atherosclerosis and inflammation: an update. Toxicol Pathol. 2001;29:224-231.
5. Chawla A, Schwartz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR) g: adipose-predominant expression and induction early in adipose differentiation. Endocrinology. 1994;135:798-800.
6. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARg2, a lipid-activated transcription factor. Cell. 1994;79:124-130.
7. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953-12956.
8. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995;83:813-819.
9. Cavallerano J. Ocular manifestations of diabetes mellitus. Optom Clin. 1992;2:93-116.
10. Sanders RJ, Wilson MR. Diabetes-related eye disorders. J Natl Med Assoc. 1993;85:104-108.
11. Margolis KL, Rich EC. Open-angle glaucoma Prim Care. 1989;16:197-209.
12. Lam TT, Abler AS, Kwong JM, Tso MO. N-methyl-D-aspartate (NMDA)-induced apoptosis in rat retina. Invest Ophthalmol Vis Sci. 1999;40:2391-2397.
13. Lucas DR, Newhouse JP. The toxic effects of sodium L-glutamate on the inner layers of the retina. Arch Ophthalmol 1957;58:193-201.
14. Otori Y, Wei JY, Barnstable C. Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest Ophthalmol Vis Sci. 1998;39:972-981.
15. Vorwerk C, Lipton S, Zurakowski D, et al. Chronic low dose glutamate is toxic to retinal ganglion cells: toxicity blocked by memantine. Invest Ophthalmol Vis Sci. 1996;37:1618-1624.
16. Brooks DE, Garcia GA, Dreyer E, Zurakowski D, Franco-Bourland RE. Vitreous body glutamate concentrations in dogs with glaucoma. Am J Vet Res. 1997;58:864-867.
17. Carter-Dawson L, Crawford MLJ, Harwerth RS, et al. Vitreal glutamate concentration in monkeys with experimental glaucoma. Invest Ophthalmol Vis Sci. 2002;43:2633-2637.
18. Dkhissi O, Chanut E, Wasowicz M, et al. Retinal TUNEL-positive cells and high glutamate levels in vitreous humor of mutant quail with glaucoma like disorder. Invest Ophthalmol Vis Sci. 1999;40:990-995.
19. Dreyer E, Zurakowski D, Schumer R, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114:299-305.
20. Levkovitch-Verbin H, Quigley HA, Kerrigan-Baumrind LA, D'Anna SA, Kerrigan D, Pease ME. Optic nerve transection in monkeys may result in secondary degeneration of retinal ganglion cells. Invest Ophthalmol Vis Sci. 2001;42:975-982.
21. Osborne NN, Ugarte M, Chao M, et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol. 1999;43:S102-S128.
22. Suzuki YS, Forman HJ, Sevanian A. Oxidants as stimulators of signal transduction. Free Radic Biol Med. 1997;22:269-285.
23. Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin Nutr Metab Care. 2002;5:561-568.
24. Haefliger IO, Lietz A, Griesser SM. Modulation of Heidelberg Retinal Flowmeter parameter flow at the papilla of healthy subjects: effect of carbogen, oxygen, high intraocular pressure, and beta-blockers. Surv Ophthalmol. 1999;43:S59-S65.
25. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA, Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci. 1995;92:7162-7166.
26. Krisnamoorthy RR, Agarwal P, Prasanna G, et al. Characterization of a transformed rat retinal ganglion cell line. Mol Brain Res. 2001;86:1-12.
27. Krishnamoorthy RR, Crawford MJ, Chaturvedi MM, et al. Photo-oxidative stress down-modulates the activity of nuclear factor-kB via involvement of caspase-1, leading to apoptosis of photoreceptor cells. J Biol Chem. 1999;274:3734-3743.
28. Shimamoto K, Lebrun B, Yasuda-Kamatani Y, et al. DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998;53:195-201.
29. Ransom RW, Stec NL. Inhibition of N-methyl-D-aspartate evoked sodium flux by MK-801. Brain Res. 1988;444:25-32.
30. Murata T, He S, Hangai M, et al. Peroxisome proliferator-activated receptor-γ ligands inhibit choroidal neovascularization, Invest Ophthalmol Vis Sci. 2000;41:2309-2317.
31. Ershov AV, Bazan NG. Photoreceptor phagocytosis selectively activates PPAR gamma expression in retinal pigment epithelial cells. J Neurosci Res. 2000;60:328-337.
32. Kawasaki A, Han MH, Wei JY, Hirata K, Otori Y, Barnstable CJ. Protective effects of arachidonic acid on glutamate neurotoxicity in rat retinal ganglion cells. Invest Ophthalmol Vis Sci. 2002;43:1835-1842.
33. Luo X, Heidinger V, Picaud S, et al. Selective excitotoxic degeneration of adult pig retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci. 2001;42:1096-1106.
34. NN Osborne, Wood JP, Melena J, et al. 5-Hydroxytryptamine 1A agonists: potential use in glaucoma: evidence from animal studies. Eye. 2000;14:454-463.
35. Pang IH, Wexler EM, Nawy S, DeSantis L, Kapin MA, Protection by eliprodil against excitotoxicity in cultured rat retinal ganglion cells. Invest Ophthalmol Vis Sci. 1999;40:1170-1176.
36. Uryu S, Harada J, Hisamoto M, Oda T. Troglitazone inhibits both postglutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Brain Res. 2002;924:229-236.
37. Aoun P, Martin MW, Simpkins JW. 15-deoxy-delta-12,14-prostaglandin J2, a PPAR-gamma ligand, is neuroprotective. Soc Neurosci Abstr. 2001;773:19.
38. Rovin BH, Lu L, Cosio A. Cyclopentenone prostaglandins inhibit cytokine-induced NF-kB activation and chemokine production by human mesangial cells. Am Soc Nephrol. 2001;12:1659-1667.
39. Boyault S, Simonin MA, Bianchi A, et al. 15-Deoxy-delta 12, 14-PGJ2, but not troglitazone, modulates IL-lbeta effects in human chondrocytes by inhibiting NF-kB and AP-1 activation pathways. FEBS Lett. 2001;501:24-30.
40. Lennon AM, Ramauge M, Dessouroux A, Pierre M. MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Delta(12-14)-prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species. J Biol Chem. 2002;277:29681-29685.
41. Nishijima C, Kimoto K, Arakawa Y. Survival activity of troglitazone in rat motoneurones. J Neurochem. 2001;76:383-390.
42. Kim EJ, Kwon KJ, Park JY, Lee SH, Moon CH, Baik EJ. Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res. 2002;941:1-10.
43. Straus DS, Pascual G, Li M, et al. 15-deoxy-delta 12, 14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA. 2000;97:4844-4849.
44. Pereira CF, Oliveira CR. Oxidative glutamate toxicity involves mitochondrial dysfunction and perturbation of intracellular Ca2+ homeostasis. Neurosci Res. 2000;37:227-236.
45. Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science. 1969;164:719-721.
46. Murphy TH, Miyamoto M, Sastre A, et al. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron. 1989;2:1547-1548.
47. Levin LA, Clark JA, Johns LK. Effect of lipid peroxidation inhibition on retinal ganglion cell death. Invest Ophthalmol Vis Sci. 1996;37:2744-2749.